Example searches

LCI Lannett Co., Inc.

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Philadelphia, PA.

Company profile

Ticker
LCI
Exchange
NYSE
Website
www.lannett.com
CEO
Timothy C. Crew
Employees
Incorporated in
Delaware
Location
Pennsylvania
Fiscal year end
Jun 30
Sector
Health Technology > Pharmaceuticals: Major
Industry (SEC)
Pharmaceutical Preparations
Pfizer • Allergan • Merck & Co. • Warner Chilcott • Teva Pharmaceutical Industries • Johnson & Johnson • ELI LILLY & Co • Bristol Myers Squibb • AbbVie • Mylan ...
SEC CIK
0000057725
Corporate docs
IRS number
230787699

LCI stock data

(
)
FINRA relative short interest over last month (20 trading days) ?

Calendar

6 Feb 20
7 Apr 20
30 Jun 20

News

Company financial data Financial data

Chart LCI financial data
Quarter (USD) Dec 19 Sep 19 Jun 19 Mar 19
Revenue 136.11M 127.34M 133.84M 172.79M
Net income 5.08M -12.16M -7.59M 10.65M
Diluted EPS 0.13 -0.32 -0.2 0.27
Net profit margin 3.74% -9.55% -5.67% 6.16%
Operating income 16.78M 9.4M 9.4M 33.38M
Net change in cash 18.17M -39.24M -64.96M 41.43M
Cash on hand 119.18M 101.01M 140.25M 205.21M
Cost of revenue
Annual (USD) Jun 19 Jun 18 Jun 17 Jun 16
Revenue 655.41M 684.56M 633.34M 542.49M
Net income -272.11M 28.69M -581K 44.78M
Diluted EPS -7.2 0.75 -0.02 1.2
Net profit margin -41.52% 4.19% -0.09% 8.25%
Operating income -262.32M 129.7M 86.45M 130.76M
Net change in cash 41.66M -19.15M -107.03M 24.43M
Cash on hand 140.25M 98.59M 117.74M 224.77M
Cost of revenue

Financial data from Lannett earnings reports

Recent insider trades

LCI insider ownership history Insider history
Date Owner Security Transaction Code $Price #Shares $Value #Remaining
12 Nov 19 G. Michael Landis Common Stock Payment of exercise Dispose F 8.98 1,487 13.35K 37,686
11 Nov 19 Timothy C Crew Common Stock Buy Aquire P 8.99 2,000 17.98K 186,567
9 Nov 19 John Kozlowski Common Stock Payment of exercise Dispose F 8.93 222 1.98K 50,459
9 Nov 19 G. Michael Landis Common Stock Payment of exercise Dispose F 8.93 222 1.98K 39,173
26 Oct 19 John Kozlowski Common Stock Payment of exercise Dispose F 11.87 716 8.5K 50,681
30 Sep 19 Timothy C Crew Common Stock Other Aquire J 5.14 683 3.51K 184,567
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2019

LCI institutional ownership history Ownership history
98.8% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 170 168 +1.2%
Opened positions 39 39 –
Closed positions 37 24 +54.2%
Increased positions 50 41 +22.0%
Reduced positions 49 59 -16.9%
13F shares
 Current Prev Q Change
Total value 1.85B 1.22B +52.4%
Total shares 39.84M 40.56M -1.8%
Total puts 1.28M 2.06M -37.9%
Total calls 866.1K 978K -11.4%
Total put/call ratio 1.5 2.1 -29.9%
Largest owners
 Shares Value Change
Telemus Capital 7.68M $48.53M -2.4%
BLK BlackRock 5.23M $46.11M +5.0%
D. E. Shaw & Co. 3.41M $30.1M -6.2%
JPM JPMorgan Chase & Co. 2.74M $24.13M +16.3%
Vanguard 2.36M $20.82M +3.3%
LSV Asset Management 2.08M $18.35M +3.0%
STT State Street 1.3M $11.43M +3.9%
Renaissance Technologies 1.29M $11.4M -41.6%
Dimensional Fund Advisors 789.55K $6.96M -0.7%
Arrowstreet Capital, Limited Partnership 701.98K $6.19M +71.8%
Largest transactions
 Shares Bought/sold Change
Renaissance Technologies 1.29M -920.4K -41.6%
Public Sector Pension Investment Board 669.32K +584.22K +686.5%
JPM JPMorgan Chase & Co. 2.74M +383.29K +16.3%
Cubist Systematic Strategies 0 -370.38K EXIT
Engineers Gate Manager 0 -335.51K EXIT
Citadel Advisors 12.3K -319.46K -96.3%
Connor, Clark & Lunn Investment Management 81.5K -301.13K -78.7%
Lonestar Capital Management 0 -300K EXIT
Arrowstreet Capital, Limited Partnership 701.98K +293.38K +71.8%
BLK BlackRock 5.23M +249.9K +5.0%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Impax Laboratories • Mylan
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: agreeable, Dexcel, Florida, Guam, MDL, meant, methodology, Mitigation, mutually, Nassau, Northern, Pharma, plaintiff, pronouncement, referenced, replace, slightly, Supreme, Trevose, Venlafaxine, XR
Removed: apply, behalf, created, expand, fee, fraud, horizontal, indemnification, patriae, profitability, responding, Road, scheme, study, submitted, substantial, system, Townsend, updated, vertical, violated
From filing 10-Q 2020 Q2

Financial reports

View all
10-Q
2020 Q2
Quarterly report
6 Feb 20
10-Q
2020 Q1
Quarterly report
7 Nov 19
10-K
2019 FY
Annual report
28 Aug 19
10-Q
2019 Q3
Quarterly report
7 May 19
10-Q
2019 Q2
Quarterly report
7 Feb 19
10-Q
2019 Q1
Quarterly report
8 Nov 18
10-K
2018 FY
Annual report
28 Aug 18
10-Q
2018 Q3
Quarterly report
8 May 18
10-Q
2018 Q2
Quarterly report
8 Feb 18
10-Q
2018 Q1
Quarterly report
8 Nov 17

Current reports

View all
8-K
Lannett Announces Fiscal 2020 Second-quarter Financial Results
7 Feb 20
8-K
Submission of Matters to a Vote of Security Holders
24 Jan 20
8-K
Entry into a Material Definitive Agreement
26 Nov 19
8-K
Lannett Announces Fiscal 2020 First-quarter Financial Results
8 Nov 19
8-K
Other Events
31 Oct 19
8-K
Lannett Announces Closing of $86.25 Million of Convertible Senior Notes Due 2026
27 Sep 19
8-K
Lannett Announces Pricing of $75 Million of Convertible Senior Notes Due 2026
25 Sep 19
8-K
INVESTOR PRESENTATION September 2019 © 2019 Lannett Company, Inc. All Rights Reserved. For Discussion Purposes Only
24 Sep 19
8-K
Lannett Announces Offering of $75 Million of Convertible Senior Notes Due 2026
24 Sep 19
8-K
Lannett Announces Fiscal 2019 Fourth-quarter, Full-year Financial Results; Issues Guidance for Fiscal 2020
28 Aug 19

Registration and prospectus

View all
S-3
Shelf registration
20 Dec 19
S-8
Registration of securities for employees
22 Mar 19
S-3ASR
Automatic shelf registration
13 Feb 18
S-3ASR
Automatic shelf registration
12 May 17
S-8
Registration of securities for employees
23 Jan 14
25
Voluntary exchange delisting
12 Dec 13
8-A12B
Registration of securities on exchange
2 Dec 13
424B5
Prospectus supplement for primary offering
4 Oct 13
FWP
Free writing prospectus
4 Oct 13
424B5
Prospectus supplement for primary offering
3 Oct 13

Proxies

View all
DEF 14A
Definitive proxy
6 Dec 19
DEFA14A
Additional proxy soliciting materials
21 Dec 18
DEF 14A
Definitive proxy
10 Dec 18
DEF 14A
Definitive proxy
7 Dec 17
DEF 14A
Definitive proxy
12 Dec 16
DEF 14A
Definitive proxy
8 Dec 15
PRE 14A
Preliminary proxy
27 Nov 15
DEF 14A
Definitive proxy
16 Dec 14
DEF 14A
Definitive proxy
17 Dec 13
PRE 14A
Preliminary proxy
6 Dec 13

Other

View all
EFFECT
Notice of effectiveness
27 Jan 20
CORRESP
Correspondence with SEC
21 Jan 20
CORRESP
Correspondence with SEC
9 Jan 20
CT ORDER
Confidential treatment order
27 Feb 19
UPLOAD
Letter from SEC
26 Apr 17
CORRESP
Correspondence with SEC
29 Mar 17
UPLOAD
Letter from SEC
16 Mar 17
CORRESP
Correspondence with SEC
7 Mar 17
UPLOAD
Letter from SEC
23 Feb 17
UPLOAD
Letter from SEC
11 Mar 16

Ownership

View all
SC 13G/A
Lannett Co Inc
14 Feb 20
SC 13G
Beneficial ownership report
11 Feb 20
SC 13G
Beneficial ownership report
11 Feb 20
SC 13G/A
Lannett Co Inc
4 Feb 20
SC 13G
Lannett Co Inc
24 Jan 20
4
LANNETT / G. Michael Landis ownership change
14 Nov 19
4
LANNETT / Timothy C Crew ownership change
12 Nov 19
4
LANNETT / JOHN KOZLOWSKI ownership change
12 Nov 19
4
LANNETT / John Abt ownership change
12 Nov 19
4
LANNETT / G. Michael Landis ownership change
12 Nov 19